{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-088606","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.451009+00:00","generated_at":"2026-05-31T09:37:11.843821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint","bullets":["Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.","R&D expense $8.2M (Q2 2024) vs $6.3M (Q2 2023); G&A $6.4M vs $2.0M.","CLOVER WaM study: 80% ORR, 56.4% MRR exceeded primary endpoint of 20% MRR; median prior lines of therapy was 4.","NDA filing for iopofosine I 131 in WM planned for Q4 2024; accelerated 6-month review; potential 2025 launch.","Raised $19.4M in July 2024; cash runway into Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-088606","json":"https://secwatch.observer/filing/0001104659-24-088606.json","markdown":"https://secwatch.observer/filing/0001104659-24-088606.md","text":"https://secwatch.observer/filing/0001104659-24-088606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/0001104659-24-088606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924088606/tm2421529d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:37:11.843821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}